Resource Logo

New drugs garner interest; but inhibitors lose shine.


AIDS Alert. 1998 Sep;13(9):99-100. Unique Identifier : AIDSLINE

Researchers at the 12th Worlds AIDS Conference in Geneva provided a strong case for offering alternative drug options to patients. Resistance problems continue to accompany protease inhibitors, but other studies are identifying new options for extended therapy, such as using abacavir or efavirenz in combination therapies, or by using Nevirapine (Viramune) with Stavudine (d4T) and Didanosine (ddI). Hydroxyurea, a cancer fighting drug, is also gaining support as an HIV treatment, because it inhibits the enzyme that HIV needs to replicate. One study revealed that combining Hydroxyurea, ddI, and Indinavir provided quick and long-lasting reductions in viral load. Conference presentations about mother-to-infant HIV transmission showed reductions in the number of vertical transmissions when Zidovudine preventive therapy was used.

NEWSLETTER ARTICLE MEETING REPORT Anti-HIV Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Disease Transmission, Vertical/PREVENTION & CONTROL Drug Therapy, Combination Female HIV Infections/*DRUG THERAPY/TRANSMISSION HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Human Patient Compliance Pregnancy Pregnancy Complications, Infectious Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE/ THERAPEUTIC USE Viral Load


Information in this article was accurate in September 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.